Chiricozzi A, De Simone C, Fossati B, Peris K. Psoriasis: Targets and Therapy. 2019;9:29–35.
The authors of this paper have advised us that by mistake they uploaded the wrong figure files for Figures 2 and 3 which had not been correctly updated.
Figure 2.
Bimekizumab efficacy in treating plaque psoriasis patients, assessed in a phase II trial. Clinical outcomes in psoriasis patients after 12-week therapy with placebo or different bimekizumab dosages.
Abbreviations: BKZ, bimekizumab; BSA, body surface area; IGA, investigator global assessment; N, number; PASI, psoriasis area severity index; pts, patients; Q4, every 4 weeks; R, randomization; tot., total; w, weeks.
Figure 3.
Bimekizumab efficacy in treating psoriatic arthritis patients, assessed in a phase II trial. Clinical outcomes in psoriatic arthritis patients after 12-week therapy with placebo or different bimekizumab dosages.
Abbreviations: ACR, American College of Rheumatology; BKZ, bimekizumab; CASPAR, Classification Criteria for Psoriatic Arthritis; N, number; pts, patients; Q4, every 4 weeks; R, randomization; SJC, swollen joint count; TJC, tender joint count; tot., total; w, weeks.
In Figure 2, the percentages within the figure do not match with what is reported in the text. As a result, they have provided the correct artwork below which should replace the existing image for Figure 2 in their paper.
In Figure 3, to be consistent with Figure 2, the author has changed just one label of one treatment group. As a result, they have provided the correct artwork below which should replace the existing image for Figure 3 in their paper.